Evommune EVMN Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect at other companies
Other financials
Where this comes from
Reported directly by Evommune in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect.
The official record: Evommune ’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Evommune 's cash cash equivalents restricted cash and restricted cash equivalents period increase decrease excluding exchange rate effect.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Evommune 's cash cash equivalents restricted cash and restricted cash equivalents period increase decrease excluding exchange rate effect?
- Evommune (EVMN) reported cash cash equivalents restricted cash and restricted cash equivalents period increase decrease excluding exchange rate effect of -$1.65M in Q1 2026.
- What does cash cash equivalents restricted cash and restricted cash equivalents period increase decrease excluding exchange rate effect mean?
- Represents the net change in the total balance of cash, cash equivalents, and restricted cash during the reporting period. This metric provides a high-level view of the company's overall liquidity position and cash flow health.